Patients treated with the SQ-grass SLIT-tablet, N (%) 1,109 (100.0)
Median Age, y (range) 35.0 (11-80)
Sex, N (%)  
Men 520 (46.9)
Women 589 (53.1)
Patients with asthma, N (%) 249 (22.5)
Patients with moderate to severe symptoms in previous season*, N (%)  
Nose 1,047 (94.4)
Eyes 863 (77.8)
Bronchi 241 (21.7)
Patients with symptomatic medication in previous season, N (%) 920 (83.2)
Satisfaction with symptomatic treatment in previous season, N (%)  
Very satisfied 32 (3.5)
Satisfied 298 (32.6)
Dissatisfied 539 (59.0)
Very dissatisfied 44 (4.8)
Missing values   7 (0.6)
Patients with concomitant AIT, N (%) 75 (6.8)
Status of immunotherapy, N (%)  
Patients first treated with AIT 741 (67.0)
Patients treated with the SQ grass SLIT-tablet after previous AIT 308 (27.8)
Patients who changed from another AIT 57 (5.2)
Missing values   3 (0.3)
N=Number of patients, SLIT=Sublingual immunotherapy, AIT=Allergy immunotherapy
*moderate: marked symptoms, moderate interference with the patients daily activities, severe: considerable interference with the patients daily activities, unacceptable for the patient
Table 1: Patient characteristics.
Goto home»